Page 92 - 《中国药房》2023年15期
P. 92

·药物与临床·


          胆宁片等3种药物预防ERCP术后胆总管结石复发的效果比较
                                                                                                         Δ

          施颖琦 ,沈美琴,仇建伟(南通市第一人民医院消化内科,江苏 南通 226000)
                *

          中图分类号  R969.4;R975+.5      文献标志码  A      文章编号  1001-0408(2023)15-1874-05
          DOI  10.6039/j.issn.1001-0408.2023.15.16

          摘   要  目的  比较胆宁片、牛磺熊去氧胆酸和熊去氧胆酸预防内镜逆行胰胆管造影(ERCP)术后患者胆总管结石复发的效果。
          方法  回顾性分析南通市第一人民医院2017年1月-2020年1月153例行ERCP胆总管取石术患者的临床资料,根据患者术后接
          受药物治疗的不同分为3组,即胆宁片组(A组,49例)、牛磺熊去氧胆酸组(B组,44例)和熊去氧胆酸组(C组,60例)。以上各组药
          物均为单用,分别于术后2周开始使用,疗程均为180 d。比较3组患者ERCP术后6个月的胆汁成分指标[血清总胆红素(Tbil)、直
          接胆红素(Dbil)、碱性磷酸酶(ALP)、谷氨酰转移酶(GGT)],脂代谢指标[血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白
         (LDL)、高密度脂蛋白(HDL)]水平,临床症状(腹痛、腹胀、恶心、纳差)发生情况及术后6、12、18、24个月胆总管结石复发情况。结
          果  与术前比较,3组患者术后6个月的血清Tbil、Dbil、ALP、GGT、TC、TG、LDL水平均显著降低(P<0.05),血清HDL水平均显著
          升高(P<0.05),发生腹痛、腹胀、恶心、纳差的患者占比均显著降低(P<0.05)。A、B组患者的Tbil水平显著低于C组(P<0.05),
          A组患者的Dbil、ALP水平均显著低于B、C组(P<0.05),但3组患者的GGT水平比较差异无统计学意义(P>0.05);相较于A、C
          组,B组患者的4个脂代谢指标水平均得到显著改善(P<0.05);A组发生腹痛、腹胀、纳差的患者占比明显低于B、C组(P<0.05),
          但3组发生恶心症状的患者占比差异无统计学意义(P>0.05)。术后6、12、18个月时,3组患者的胆总管结石复发率比较,差异均
          无统计学意义(P>0.05);术后 24 个月时,A 组患者的胆总管结石复发率(2.04%)显著低于 B 组(15.91%)和 C 组(15.00%)(P<
          0.05)。结论  ERCP术后应用胆宁片相较于应用牛磺熊去氧胆酸和熊去氧胆酸,更有利于减少胆汁酸分泌、预防胆结石复发、改善
          临床症状,但牛磺熊去氧胆酸较其他2种药物更能明显加速患者脂代谢。
          关键词  胆宁片;牛磺熊去氧胆酸;熊去氧胆酸;内镜逆行胰胆管造影;胆总管结石;复发

          Comparison  of  the  efficacy  of  3  kinds  of  drugs  such  as  Danning  tablet  on  preventing  the  recurrence  of
          choledocholithiasis after endoscopic retrograde cholangiopancreatography
          SHI Yingqi,SHEN Meiqin,QIU Jianwei(Dept.  of  Gastroenterology,  Nantong  First  People’s  Hospital,  Jiangsu
          Nantong 226000, China)


          ABSTRACT    OBJECTIVE  To  compare  the  efficacy  of  Danning  tablet,  taurosodeoxycholic  acid  and  ursodeoxycholic  acid  in
          preventing  the  recurrence  of  choledocholithiasis  after  endoscopic  retrograde  cholangiopancreatography (ERCP).  METHODS  The
          clinical  data  of  153  patients  who  underwent  ERCP  choledocholithotomy  from  January  2017  to  January  2020  in  Nantong  First
          People’s  Hospital  were  retrospectively  analyzed.  According  to  the  different  drug  treatment  received  after  surgery,  patients  were
          divided  into  three  groups,  namely,  Danning  tablet  group (group  A,  49  cases),  tauroursodeoxycholic  acid  group (group  B,  44
          cases)  and  ursodeoxycholic  acid  group (group  C,  60  cases). The  above  groups  of  drugs  are  all  single-use,  starting  from  2  weeks
          after  surgery  for  a  course  of  180  days.  The  effects  of  bile  component  indicators  [total  bilirubin (Tbil),  direct  bilirubin (Dbil),
          alkaline phosphatase (ALP), glutamyltransferase (GGT)], lipid metabolism indicators [total cholesterol (TC), triglyceride (TG),
          low-density lipoprotein (LDL), high-density lipoprotein (HDL)], the occurrence of clinical symptoms (abdominal pain, bloating,
          nausea,  and  poor  appetite)  at  6  months  after  ERCP,  and  the  recurrence  of  choledocholithiasis  at  6,  12,  18  and  24  months  after
          surgery  were  compared  among  3  groups.  RESULTS  Compared  with  before  surgery,  the  serum  levels  of Tbil,  Dbil, ALP,  GGT,
          TC,  TG  and  LDL  were  significantly  reduced (P<0.05),  while  serum  HDL  levels  were  significantly  increased (P<0.05)  in  the
          three  groups  at  6  months  after  surgery.  The  proportion  of  patients  who  experienced  abdominal  pain,  bloating,  nausea,  and  poor
          appetite at 6 months after surgery was significantly reduced (P<0.05). The Tbil levels of groups A and B were significantly lower
                                                              than  those  of  group  C (P<0.05),  while  the  Dbil  and  ALP
              Δ 基金项目 江苏省重点研发计划项目(No.JS2021SD122)
             *第一作者 副主任医师,硕士。研究方向:炎症性肠病、胆总管结                   levels of group A were significantly lower than those of groups
          石、消化道早癌。E-mail:shiyq2012@163.com                    B  and  C (P<0.05);  however,  there  was  no  statistically


          · 1874 ·    China Pharmacy  2023 Vol. 34  No. 15                            中国药房  2023年第34卷第15期
   87   88   89   90   91   92   93   94   95   96   97